A patient is receiving mitoxantrone (Novantrone) for treatment of secondary progressive multiple sclerosis (MS). This patient should be closely monitored for
a) hypoxia.
b) renal insufficiency.
c) mood changes and fluid and electrolyte alterations.
d) leukopenia and cardiac toxicity.
Asnwer: leukopenia and cardiac toxicity.
If the answers is incorrect or not given, you can answer the above question in the comment box. If the answers is incorrect or not given, you can answer the above question in the comment box.